A growing number of complex older adults are referred for electrophysiological conditions and age alone is insufficient to guide management decisions such as implantable cardioverter-defibrillator (ICD) implantation or atrial fibrillation anticoagulation. The concept of frailty has emerged as a geriatric vital sign to gain insight into physiological reserve and prognostic risk beyond chronological age and comorbidities. To date, a number of published studies have evaluated frailty in patients with electrophysiological conditions. These studies collectively demonstrate that frail patients have an increased prevalence of atrial fibrillation, lower use of oral anticoagulation, higher risk of bleeding complications from oral anticoagulation, and higher risk of stroke and mortality. A paucity of studies have explored frailty in the setting of device implantation, with a signal suggesting that frail heart failure patients may have a lower likelihood of being considered for ICD and cardiac resynchronization therapy devices, and a higher risk of fatal and nonfatal events after ICD and cardiac resynchronization therapy implantation. Whether frailty modulates the risks and benefits of these devices is a critical knowledge gap for which further study is clearly warranted. (J Am Coll Cardiol EP 2016;2:288-94) 
T he burden of electrophysiological (EP) disease in older adults is continuously rising.
Atrial fibrillation (AF) and sick sinus syndrome are regarded as "geriatric conditions," whereas ventricular arrhythmias in failing hearts also affect the elderly in large numbers. Reflecting the advancing age of the general population, the prevalence of AF has reached 3 million in the United States and will continue to increase up to 7.5 million by 2050 (1) . The implantation of permanent pacemakers has similarly increased by 56% over the past 10 years (2) , and an international survey showed that virtually all 61 countries surveyed had steady increases in implantations of pacemaker and implantable cardioverter-defibrillator (ICD) devices (3) . The appropriateness of prophylactic ICD implantation in the very elderly remains a topic of great debate, with ethical and economical considerations, and widespread variability in practice.
As the EP practitioner is faced with a growing referral base of complex elderly patients, it has become clear that age alone is insufficient to characterize these patients and determine their eligibility for therapies such as ICD or AF anticoagulation. The concept of frailty has emerged as a means of better characterizing the resiliency of older adults beyond their age and comorbidities, in order to refine estimates of predicted risk and guide decisions for individualized care. Thus, the objective of this review is to define frailty for the EP practitioner and synthesize 
FRAILTY DEFINED
Frailty is a geriatric syndrome caused by subclinical impairments in multiple organ systems leading to loss of homeostatic reserve and resiliency. Under physiological stress, be it from illness or iatrogenesis, frail patients suffer a higher rate of fatal and nonfatal complications, functional decline, and disability (4).
One of the central impairments is age-related loss of muscle mass and strength known as sarcopenia, which has been operationally defined by a number of phenotypic criteria: slow walking speed, weak muscle strength, unintentional weight loss, low physical activity, and exhaustion (Fried's scale) (5) . Tools have been developed to objectively and rapidly quantify these phenotypic criteria and the interrelated domains of cognition, disability and mood in the clinical setting ( Table 1 ) (6). These tools have been adopted in the fields of cardiac surgery, transcatheter valve implantation, heart failure, and ischemic heart disease, but they have yet to achieve meaningful penetration in the field of EP.
The utility of frailty in EP was highlighted by a joint consensus document from the French Societies of Cardiology and Gerontology, which recommended frailty assessment to help guide decisions about AF anticoagulation in the elderly. However, Hanon et al.
(7) cautioned that there was a paucity of evidence and that further studies were needed before endorsing implementation of frailty scores. Since then, a number of studies have been published on the topic of frailty in AF and device implantation ( Table 2) , and there is an unmet need to synthesize the lessons learned from these studies for the practicing clinician and identify knowledge gaps for future research.
IMPLICATIONS OF FRAILTY FOR AF CARE
One of the first observations made in the literature is that frail AF patients are significantly less likely to receive oral anticoagulation therapy (OAC) compared to their nonfrail counterparts. Perera et al. (8) other risk factors were heart failure, increased heart rate, and AF symptom class (17) . The ORBIT-AF group developed a risk model to predict major bleeding events in older adults receiving OAC (18) . Although frailty was not selected for inclusion in the final model, unpublished data provided by the authors revealed that the prevalence of frailty was significantly greater in patients that experienced a major 
Bibas et al. However, frailty seemed to be a risk factor for not being therapeutic on OAC, with only 21% of patient in target range.
Thus, the evidence demonstrates that frail patients are 2 to 8 times less likely to receive OAC therapy for stroke prevention in AF, despite the fact that they are at higher risk of subsequent stroke and mortality. An analysis from 5,888 participants in the Cardiovascular Health Study showed that frailty (as measured by slow gait speed) was an independent risk factor for strokerelated mortality, including cardioembolic and noncardioembolic strokes (22 (24, (33) (34) (35) .
Another common risk factor between frailty and AF is impairment in cardiac autonomic control as evidenced by decreased HRV (36, 37) . Studies have shown that decreased HRV often precedes episodes of paroxysmal AF and, in an analysis from the Framingham Heart Study, that it may be predictive of incident AF (35) . Low-frequency oscillation was the HRV parameter that best predicted new-onset AF in a middle-aged Finnish cohort (38) . Similarly, decreased HRV has garnered interest as a candidate biomarker for frailty. The rationale being that the healthy cardiovascular system is characterized by a dynamic complexity that is charged with detecting and adapting to various changes in order to maintain homeostasis-the high variability in our basic heart rate is proof of this concept. As we age, clinical and subclinical impairments in cardiovascular physiology render the system less dynamic and complex, and thus heart rate less variable (39) .
IMPLICATIONS OF FRAILTY FOR DEVICE IMPLANTATION
Use of ICDs for primary prevention in older adults remains controversial and polarizing within the EP Fried scale consists of slowness, weakness, physical inactivity, weight loss, and exhaustion, with $3/5 positive items required to classify a patient as frail. *Patient is asked to walk at a comfortable pace from 0-m start line to past 5-m finish line, cue to start and stop stopwatch is first footfall after start line and first footfall after finish line, repeated 3 times and average time is recorded. †Patient is asked to squeeze a handgrip dynamometer as hard as possible, repeated 3 times (with each hand and then with strongest hand) and maximum value is recorded.
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community, particularly at the extremes of age (>80 to 90 years of age) (40 Twenty-nine patients were identified as frail (28%).
Frailty was a strong predictor of the primary endpoint of decompensated heart failure over 1 year of follow-up after CRT with defibrillator implantation (hazard ratio: 4.55; 95% CI: 1.73 to 12.01) (49) . In our experience, the improvement in physical function observed after CRT implantation often leads to improvements in gait speed and frailty scores (i.e., "defrails" patients). Prophylactic ICD therapy does not necessarily have the same effect because its desired effect is prevention of sudden cardiac death, which occurs in a minority of patients and is superseded by death from non-arrhythmogenic causes in most frail elders.
KNOWLEDGE GAPS
The studies identified were skewed toward AF, with Frailty is associated with an increased prevalence of atrial fibrillation and heart failure. Although frail patients are more likely to suffer fatal and nonfatal events, they are less likely to be treated with anticoagulation therapy for atrial fibrillation and implantable cardioverter-defibrillator or cardiac resynchronization device therapy for heart failure. Further research is needed to elucidate the risks and benefits of these therapeutic interventions in frail patients and accordingly determine whether this treatment paradox is justified (or not).
Frailty in Elderly EP Patients J U N E 2 0 1 6 : 2 8 8 
CONCLUSIONS AND RECOMMENDATIONS
This review has highlighted the relevance of frailty in predicting risk and guiding treatment decisions for older adults with EP conditions (Central Illustration). jonathan.afilalo@mcgill.ca.
